<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927732</url>
  </required_header>
  <id_info>
    <org_study_id>06/2-D</org_study_id>
    <nct_id>NCT00927732</nct_id>
  </id_info>
  <brief_title>Hydroquinidine Versus Placebo in Patients With Brugada Syndrome</brief_title>
  <acronym>Quidam</acronym>
  <official_title>BRD 06/2-D (Quidam) &quot;Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this study is to determine whether hydroquinidine administration can
      prevent heart from appearance of ventricular arrhythmia detected by the automatic implantable
      defibrillator (ICD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During this double-blind randomized cross-over study, patient will receive during 18 months
      treatment 1 (hydroquinidine or placebo) and, after 7 days of wash-out, patient will receive
      treatment 2 (meaning for example hydroquinidine if treatment 1 was placebo). Time length
      before arisen of an appropriate shock registered on the defibrillator (meaning due to
      ventricular arrhythmia) will be assessed during treatment 1 period and treatment 2 period.We
      hypothesized that hydroquinidine administration will enhance time length before arisen of an
      appropriate shock and thus mean that hydroquinidine administration can prevent heart from
      appearance of ventricular arrhythmia. Patient's defibrillator recordings will be analysed
      every 6 months plus when patient experiences an ICD shock. If the shock delivered by the ICD
      is appropriate and happens during treatment 1 period, patient will switch to treatment 2
      period after 7 days of wash-out. If the shock delivered by the ICD is appropriate and happens
      during treatment 2 period, study will be finished for this patient.Before starting the study,
      each patient will test which dose of hydroquinidine she/he requires to have an hydroquinidine
      concentration in her/his blood included between 3 and 6 µmol/L.

      Planned enrollment: 200 subjects (60 being symptomatic with histories of aborted sudden
      cardiac death or of ventricular fibrillation, 70 being symptomatic with histories of syncope
      considered as of arrhythmic origin, 70 being asymptomatic with a spontaneous type 1 ECG and a
      positive electrophysiological exploration)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient recruitment, a lot of premature study discontinuations
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether hydroquinidine enhances time length before arisen of an appropriate shock registered on the automatic implantable defibrillator (meaning due to ventricular arrhythmia)</measure>
    <time_frame>3 years after patient randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate number and frequency of inappropriate shock with and without hydroquinidine</measure>
    <time_frame>3 years after patient randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the number of tachycardia or of ventricular fibrillations detected by the defibrillator but not having required any treatment</measure>
    <time_frame>3 years after patient randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate number of syncope reported by the patient but for which no ventricular arrhythmias has been detected by the defibrillator</measure>
    <time_frame>3 years after patient randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the number and frequency of adverse events appeared under hydroquinidine treatment</measure>
    <time_frame>3 years after patient randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate interest of the electrophysiological exploration for determining chances of success of an hydroquinidine</measure>
    <time_frame>3 years after patient randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Brugada Syndrome</condition>
  <arm_group>
    <arm_group_label>hydroquinidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>capsules of sugar</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroquinidine</intervention_name>
    <description>capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization</description>
    <arm_group_label>hydroquinidine</arm_group_label>
    <other_name>Hydroquinidine is commercialized as Serecor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (sugar)</intervention_name>
    <description>capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine</description>
    <arm_group_label>capsules of sugar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult (at least 18 years of age)

          -  Informed consent form signed

          -  Subject affiliated to French health insurance (Sécurité Sociale)

          -  Type 1 Brugada syndrome either symptomatic or asymptomatic

          -  Not pregnant, taking oral contraceptive measure if able to procreate

          -  If patient with asymptomatic type 1 Brugada, electrophysiological exploration must be
             positive at study inclusion

          -  No current intake of &quot;betablocking&quot; medicine used in cardiac insufficiency
             (bisoprolol, carvedilol, metoprolol)

          -  No current myasthenia

          -  No current treatment with halofantrine, pentamidine, moxifloxacin

          -  No current treatment with some neuroleptics

          -  Known hypersensitivity to hydroquinidine

          -  Intolerance to fructose, syndrome of glucose or galactose malabsorption, deficit in
             sucrase isomaltase- Cardiac insufficiency

          -  Histories of &quot;torsades de pointe&quot;

          -  Intake of medicine giving &quot;torsades de pointe&quot;

        Exclusion Criteria:

          -  Subject not fulfilling inclusion criteria

          -  Subject being before study entry under hydroquinidine treatment but either at a dose &gt;
             3 capsules per day or at a dose of 1, 2 or 3 capsules per day but with a plasmatic
             hydroquinidine concentration &gt;6µmol/L or &lt;3 µmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>V Probst, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU NANTES - Hôpital Laennec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JM Dupuis, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JS Hermida, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU AMIENS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Haissaguerre, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU BORDEAUX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Mansourati, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU BREST</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P Defaye, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S Kacet, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P Chevallier, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JC Deharo, pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU MARSEILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JM Davy, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N Sadoul, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU NANCY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Leenhardt, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU PARIS LARIBOISIERE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Amiel, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU POITIERS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P Mabo, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU RENNES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Chauvin, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU STRASBOURG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D Babuty, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU TOURS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P Maury, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU TOULOUSE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Paris Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>November 21, 2014</last_update_submitted>
  <last_update_submitted_qc>November 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brugada</keyword>
  <keyword>hydroquinidine</keyword>
  <keyword>ventricular arrhythmia</keyword>
  <keyword>patients with Brugada syndrome, high cardiac arrhythmic risk and implanted with an implantable cardioverter defibrillator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroquinidine</mesh_term>
    <mesh_term>Quinidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

